Revolutionary Cancer Treatment Could Transform Patient Outcomes by 2027

A groundbreaking cancer treatment developed in Wellington, New Zealand, has shown promise in putting patients with terminal diagnoses into long-term remission. The treatment, known as CAR T-cell therapy, may be available through the public healthcare system as early as 2027, pending necessary approvals from health authorities. This development could provide hope to patients who currently face expensive treatments abroad.

BioOra Limited, a biotech company partly owned by the Malaghan Institute of Medical Research, is preparing to manufacture CAR T-cell therapy on a larger scale. This follows the completion of a trial run by the institute, which has yielded encouraging results. The therapy, already a standard treatment for certain blood cancers in countries like Australia, is not yet available in New Zealand’s public or private systems.

The company is in the process of building a state-of-the-art manufacturing facility in Christchurch. This facility will utilize an automated system to produce the therapy safely and efficiently, minimizing contamination risks. Managing Director John Robson expressed concerns that delays in public system approval could hinder access for patients in need. “We’re kind of on this knife edge of, will they go fast enough for us?” Robson stated, emphasizing the urgency of securing funding to align with production timelines.

CAR T-cell therapy involves harvesting a patient’s immune cells, genetically modifying them to target cancer cells, and reinfusing them back into the patient’s bloodstream. This form of treatment has been transformative for many patients abroad, but New Zealand’s healthcare system has yet to integrate it. The Malaghan Institute is working to change this, having already developed its own version of CAR T that achieved remarkable results in a phase 1 clinical trial. Over half of the lymphoma patients who were out of treatment options saw their cancer cleared within months, with fewer serious side effects compared to commercial therapies available internationally.

Phase 2 of the trial is set to enroll its final patient by October 2023, with results expected soon thereafter for regulatory approval from Medsafe. This body will review the therapy over a three to six-month period. Robson noted that there is a regulatory pathway that could allow the therapy to be offered privately before Medsafe approval is granted. However, to provide public access simultaneously would require special government funding.

The anticipated cost per patient is projected to be significantly lower than the current $1 million charged in Australia and the United States, and only slightly higher than the approximately $200,000 charged in other markets, such as China. Robson did not disclose specific figures but emphasized the treatment’s potentially lower cost coupled with its safety profile. “The global story for us is that this is a safer immunotherapy than anything else that’s currently approved,” he stated.

In addition to its manufacturing goals, BioOra aims to reinvest a substantial portion of its profits back into the Malaghan Institute to fund further research and development of CAR T therapies and other immunotherapies. The company has ambitions to treat a variety of conditions, including childhood acute lymphoblastic leukaemia and other blood and solid tumor cancers.

BioOra is also exploring the possibility of establishing a manufacturing facility in Australia, which could streamline the treatment process for patients across the Tasman Sea. Currently, the transportation of samples to labs in the United States or Europe adds significant delays for patients who cannot afford to wait.

The Malaghan Institute recently launched a campaign to raise $17 million to cover the costs of the phase 2 trial, separate from the funding raised by BioOra. Robson highlighted that the upfront costs of CAR T-cell therapy might seem high, but they represent a one-time treatment that could replace years of costly hospital visits and invasive interventions.

As BioOra prepares for the commercial launch of CAR T-cell therapy, the need for swift action from health officials becomes increasingly critical. Robson pointed out, “If you have a 20 or 30-year-old that’s treated and they effectively go down this curative pathway, their benefit and their input to New Zealand is huge.”

Officials at Te Aho o Te Kahu, the Cancer Control Agency, are coordinating with various health entities to assess the implications of introducing CAR T-cell therapy into the healthcare system. The anticipated introduction of the Medical Products Bill this year aims to create more flexible approval pathways for innovative treatments like CAR T-cell therapy, although implementation may not occur until late 2030.

The future of this revolutionary treatment hangs in the balance, with the potential to reshape cancer care in New Zealand. As BioOra works towards its goal of becoming a global leader in immunotherapy, the urgency for public access to CAR T-cell therapy grows, offering new hope to patients facing dire circumstances.